FURFINE, ERIC E,‧弗法恩,DIX, DANIEL D,‧迪克斯,GRAHAM, KENNETH, S. KS,‧格雷厄姆,FRYE, KELLY K,‧弗賴伊
申请号：
HK15105252.5
公开号：
HK1204580A
申请日:
2015.06.02
申请国别(地区):
HK
年份:
2015
代理人:
摘要：
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence showing in SEQ ID No: 4 or amino acids 27-457 of SEQ ID No: 4.
